MedTrace Logo

The Effects of EstroSense®/MD vs Placebo in Improving the Estrogen Profile in Females

NCT02385916 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2023-05-10

No results posted yet for this study

Summary

According to the Canadian Cancer Society, 1 in 9 Canadian women will develop breast cancer in her lifetime and 1 in 30 will die. The single greatest risk factor of breast cancer is poor estrogen metabolism. EstroSense®/MD is a natural health product that promotes and supports healthy estrogen metabolism. It may increase the ratio of "good estrogen" to "bad estrogen" and potentially reducing the risk of breast cancer. For this proposed study, the investigators will be examining the effect of EstroSense®/MD compared to placebo, on estrogen metabolism in 120 women.

Conditions

  • Estrogen Profile

Interventions

OTHER

EstroSense®/MD

A natural product already approved by Health Canada

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2019-03-31
Completion
2020-04-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02385916 on ClinicalTrials.gov